We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » LILLY RESOLVES GMP PROBLEMS; INDUSTRY WARY OF ENFORCEMENT
LILLY RESOLVES GMP PROBLEMS; INDUSTRY WARY OF ENFORCEMENT
January 5, 2004
Eli Lilly has resolved FDA concerns about current GMP issues at its Indianapolis facilities, where it plans to manufacture the antidepressant Cymbalta and injectable schizophrenia drug Zyprexa, the company announced recently.